SCHEMBL18327643

SCHEMBL18327643

c1ccc(-c2ccc(-c3nc(-c4ccc(-c5ccccc5)cc4)nc(-c4cc(-c5ccccc5)cc(-c5ccc(-c6ccccc6)cn5)c4)n3)cc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
ALDH1A1 P00352 2/20 0.47
MAPT P10636 2/20 0.47
HPGD P15428 2/20 0.47
NPC1 O15118 2/20 0.47
NFKB1 P19838 2/20 0.47
RAB9A P51151 2/20 0.47
NFKB2 Q00653 2/20 0.47
RELA Q04206 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
HSD17B1 P14061 1/20 0.45
HSD17B2 P37059 1/20 0.45
NTSR1 P30989 1/20 0.43
LDHA P00338 1/20 0.42
LMNA P02545 2/20 0.41
HPGDS O60760 2/20 0.41
KDM4E B2RXH2 1/20 0.41
GLA P06280 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18327319 1.00 MEN1 (0.47) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL17343296 0.98 MEN1 (0.49) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL1370426 0.97 MEN1 (0.51) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL18327318 0.97 MEN1 (0.51) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL18327645 0.97 MEN1 (0.51) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL18325208 0.92 MEN1 (0.47) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL18325355 0.92 MEN1 (0.47) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL24608399 0.91 MEN1 (0.44) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL25449308 0.91 HPGDS (0.47) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL19506869 0.90 HPGDS (0.47) MEN1KMT2AALDH1A1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9812652-B2 Cyclic azine compound having adamantyl group, production method, and organic electroluminescent device containing it as constituent component TOSOH CORPORATION (JP) 2017-11-07 US disclosed
US-20160372678-A1 CYCLIC AZINE COMPOUND HAVING ADAMANTYL GROUP, PRODUCTION METHOD, AND ORGANIC ELECTROLUMINESCENT DEVICE CONTAINING IT AS CONSTITUENT COMPONENT TOSOH CORPORATION (JP) 2016-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160372678-A1 CYCLIC AZINE COMPOUND HAVING ADAMANTYL GROUP, PRODUCTION METHOD, AND ORGANIC ELECTROLUMINESCENT DEVICE CONTAINING IT AS CONSTITUENT COMPONENT CHRM1, AFF1, AZI2 MEN1 210/4885KMT2A 3381/4885ALDH1A1 200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.